The role of miRNAs in alveolar epithelial cells in emphysema

Hassan Hayek\textsuperscript{a,b}, Beata Kosmider\textsuperscript{a,b,c}, Karim Bahmed\textsuperscript{b,d,*}

\textsuperscript{a}Department of Microbiology, Immunology, and Inflammation, Temple University, Philadelphia, PA 19140, USA

\textsuperscript{b}Center for Inflammation and Lung Research, Temple University, Philadelphia, PA 19140, USA

\textsuperscript{c}Department of Biomedical Education and Data Science, Temple University, Philadelphia, PA 19140, USA

\textsuperscript{d}Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA 19140, USA

Abstract

Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease becoming one of the leading causes of mortality and morbidity globally. The significant risk factors for COPD are exposure to harmful particles such as cigarette smoke, biomass smoke, and air pollution. Pulmonary emphysema belongs to COPD and is characterized by a unique alveolar destruction pattern resulting in marked airspace enlargement. Alveolar type II (ATII) cells have stem cell potential; they proliferate and differentiate to alveolar type I cells to restore the epithelium after damage. Oxidative stress causes premature cell senescence that can contribute to emphysema development. MiRNAs regulate gene expression, are essential for maintaining ATII cell homeostasis, and their dysregulation contributes to this disease development. They also serve as biomarkers of lung diseases and potential therapeutics. In this review, we summarize recent findings on miRNAs’ role in alveolar epithelial cells in emphysema.

Keywords

Emphysema; Alveolar epithelial cells; MiRNA; Biomarkers

1. Introduction

The mammalian distal lung is a structurally complex and highly dynamic organ [1]. The alveoli are the lung parenchyma’s hollow structures, serve as the gas exchange site, and function as an essential barrier to protect tissue from environmental insults. The alveolar compartment is lined with two types of alveolar epithelial cells, the alveolar type II (ATII)
and alveolar type I (ATI) cells. ATII cells synthesize and secrete pulmonary surfactants. They also have a stem cell potential and differentiate into ATI cells, forming the blood-air barrier’s epithelial component [2]. Chronic exposure to various environmental insults such as cigarette smoke induces pro-inflammatory response and oxidative stress in the lung, leading to alveolar epithelial cells apoptosis, which can contribute to emphysema development [3]. Exposure to cigarette smoke induces senescence in ATII cells isolated from human and murine lungs [4]. This emphasizes their critical role in tissue homeostasis and repair after injury. Emphysema belongs to chronic obstructive pulmonary disease (COPD), and it is defined as an airspace enlargement of the lung following rupture of the alveolar walls. It most frequently develops in people > 45 years old because of smoking [5]. Lung transplantation, lung volume reduction surgery, and endoscopic lung volume reduction are the options for patients with emphysema [6]. Understanding COPD’s pathology and molecular mechanisms can lead to identifying novel potential therapeutic targets. This will result in approaches to slow down or reverse the disease development and promote lung regeneration [7,8].

MicroRNAs (miRNAs) are small regulatory RNA genes transcribed from DNA that are not translated. It was estimated that 3–4% of human genes encode miRNA [9]. MiRNAs target mRNA degradation and suppression of protein translation based on sequence complementarity between the miRNA and its targeted mRNA 3'UTR. However, the involvement of miRNAs in gene expression activation was also reported. A cumulating number of reports show a pivotal role of miRNAs in COPD [10]. Also, miRNA-based therapies may prevent and decrease alveolar epithelial cell injury; however, they are still under development for this disease.

2. Alveolar epithelial cells

ATII cells, also called type II pneumocytes, comprise 14% of all lung cells and cover 5% of the lung’s internal surface area [11]. They are smaller than ATI cells and harbor a large nucleus. ATII cells are squamous and have a cuboidal shape with an apical surface area of about 250 μm² per cell, composed of distinct microvilli. ATII cells provide many components required for the unique microenvironment in the alveolus. They have lamellar bodies (LBs) and secrete pulmonary surfactant, a lipoprotein substance necessary for proper lung function, preventing alveolar collapse by reducing surface tension at the end of expiration and exerting protective, antimicrobial properties [12]. ATII cells synthesize and release surfactant proteins (SP) A, B, C, and D [13]. SP-A plays a crucial role in pathogen clearance and inflammatory responses and stimulates phospholipids’ uptake by ATII cells. SP-B is important in LBs biogenesis. SP-C is expressed exclusively by ATII cells, facilitates lipid movement between sheets of membrane and vesicles, and functions along with SP-B to promote surfactant film formation. SP-C also stimulates the reuptake of surfactant phospholipids by ATII cells like SP-A and plays a role in surfactant recycling [14]. SP-D affects the physical structure of phospholipid aggregates in surfactant and their uptake and catabolism by ATII cells. Deletion of Sp-D in mice resulted in the pulmonary accumulation of phospholipids and increased alveolar surfactant phospholipid pools. Also, Sp-D deletion was associated with increased numbers of activated macrophages, enlarged
distal airspaces, inflammation, and increased lung volumes consistent with emphysema histologic and morphometric features [15].

ATII cells act as progenitor cells in the alveoli, proliferate, and differentiate into ATI cells (called type I pneumocytes), which comprise 8% of the peripheral lung cells [11]. ATI cells cover approximately 95% of the alveolar surface. They are thin and flat with a diameter between 50 and 100 μm, thickness between 0.1 and 0.2 μm, a small nucleus, and an overall cytoplasmic extension around 2300 μm in humans. They reside near the capillary bed and form the air-blood barrier through which gases diffuse and ensure efficient oxygen and carbon dioxide exchange between alveolar spaces and capillaries [16,17]. Also, ATI cells participate in ion and fluid transport, express both the α1 and α2 Na,K-ATPase isoforms, and are capable of active Na\(^{+}\) transport and fluid reabsorption [18]. We have shown that ATI cells are more susceptible to damage induced by environmental factors than ATII cells [19,20]. Notably, the stemness ability of ATII cells is more activated when ATI cells are injured, which contributes to alveolar renewal and restoration of epithelial integrity [21,22]. Various signaling pathways mediating ATII cell differentiation to ATI cells were identified. WNT/β-catenin, NOTCH, yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ), bone morphogenetic protein (BMP), and transforming growth factor-β (TGFβ) are among these pathways [23]. Therefore, ATII cells play a critical role in the distal lung epithelium and regeneration after injury, and their dysfunction contributes to the pathogenesis of various parenchymal lung diseases, including emphysema [22].

3. Emphysema pathophysiology

Emphysema belongs to chronic obstructive pulmonary disease (COPD) [24]. COPD is a significant contributor to morbidity and mortality worldwide and is the third leading cause of death, with 3.23 million deaths in 2019. About 80% of these deaths occur in low- and middle-income countries [25]. It is often underdiagnosed, with only 10–15% of all cases identified medically, and it rises sharply in people aged > 45 years [5,26]. Without effective prevention, COPD-related deaths would elevate by over 30% in the near few decades. Emphysema consists of a unique alveolar wall damage pattern resulting in marked airspace enlargement. This reduction in the lung surface area traps air in the damaged tissue and prevents oxygen from moving through the bloodstream [27–29]. Emphysema is characterized by tissue destruction, hyperinflation, and ventilation-perfusion mismatch.

Cigarette smoking and secondhand smoking are the key cause of the vast majority of emphysema cases [30,31]. Chronic exposure to cigarette smoke’s toxic and oxidant components causes alveolar wall damage due to the generation of reactive oxygen and nitrogen species, free radicals, and unsaturated aldehydes, which alter DNA, lipids, and proteins in alveolar epithelial cells. Genetic predisposition, age, and occupational exposures are important risk factors of emphysema development [32]. This disease can also be caused by the deficiency of an essential anti-protease in the lung, the α1-antitrypsin (AAT). This protease inhibitor plays a crucial role in modulating key immune cell activities and protecting the lung against damage caused by inflammation [33]. In a recent study, Janosz et al. investigated the pulmonary transplantation of macrophages transgenic for AAT in the
murine lungs [34]. Also, they confirmed the expression and secretion of AAT in human macrophages. Such approaches have promising therapeutic benefits for AAT deficiency.

At the cellular level, the emphysematous lung is characterized by increased numbers of alveolar macrophages, neutrophils, cytotoxic CD8+ T-lymphocytes, and the release of multiple inflammatory mediators such as lipids, chemokines, and cytokines [14,21]. The imbalance of the ongoing inflammation with activated macrophages and neutrophils contributes to reactive oxygen species (ROS) generation leading to oxidative stress. Also, the presence of damaged proteins, peroxidized lipids, and protease/anti-protease imbalance causes alveolar epithelial cell apoptosis and this disease progression [28, 35–37]. We previously showed high oxidative stress, 4-HNE, IL-8, and IL-6 levels and apoptosis in ATII cells obtained from heavy smokers [3,38]. Moreover, ATII cells are abundant in mitochondria, and we have recently reported that dysfunction of these organelles contributes to emphysema pathogenesis [3]. Together, cellular and molecular alterations lead to a matrix and tissue degradation, impeding the ATII cells’ ability to serve as progenitor cells to repopulate the injured epithelium and contributing to this disease development [27,29,39].

4. MiRNAs as biomarkers

MicroRNAs (miRNAs) are small non-coding RNAs of 19–25 nucleotides long with no ability to be translated into protein [40]. They bind to the 3’UTR or the target mRNAs’ coding region and regulate their expression post-transcriptionally through RNA degradation or translation inhibition. Therefore miRNAs are critical regulators of biological processes such as cell differentiation, proliferation, cell-cell interaction, oxidative stress, and cell death. They are essential for normal pulmonary development and maintaining lung homeostasis. Deregulation of miRNAs expression results in pathological conditions and a broad spectrum of diseases [41].

MiRNAs are mainly in the cell cytoplasm, where they are processed from precursor inactive pre-miRNAs into double-stranded mature miRNAs [42]. Only one strand of the miRNA is integrated into the RNA-induced silencing complex (RISC), which functions as gene expression regulators against its target mRNAs. Mature miRNAs exert their traditional biological function in the cytoplasm. However, recent studies have identified their localization in different cellular compartments, including exosomes, endoplasmic reticulum, nucleolus, and mitochondria. They regulate the expression of multiple target genes and signaling pathways involved in critical processes such as cell growth, proliferation, and apoptosis [43–45].

Exosomes represent a subpopulation of extracellular vesicles (EVs) released into the extracellular spaces [46]. They are present in various fluids such as blood, urine, sputum, or BAL (bronchoalveolar lavage). They have a crucial function in intercellular communication via transferring their content, including miRNAs, to target cells. About 10% of the circulating miRNAs are in exosomes [47]. The rest forms complexes with proteins such as argonaute 2 (AGO2), nucleophosmin 1 (NPM 1), or high-density lipoprotein (HDL).AGO2 is an essential catalytic component of the RISC which mediates canonical miRNA engagement with intracellular target transcripts. NPM 1 was the first protein identified as
crucial for miRNA transport and protects miRNA degradation by RNase. HDL enables the transport of lipids and fat-soluble vitamins through the bloodstream [48]. Studies reported miRNAs’ implication as clinical biomarkers for COPD and emphysema [49,50]. Their role in lung inflammation and pathogenesis of idiopathic pulmonary fibrosis (IPF), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), asthma, and lung cancer was also reported.

Exosomal miRNAs can be obtained from body fluids and used as potential non-invasive biomarkers to diagnose respiratory diseases. A recent study showed high exosomal miR-21 levels in sera of smokers and COPD patients [51]. Moreover, smoking altered EVs miRNA profile, including exosomes in the BAL fluid, compared to non-smokers [52,53]. The human bronchial epithelial BEAS-2B cell line exposed to various factors secreted exosomes containing miRNAs into the extracellular space [54,55]. Recently, Chen et al. found that exosomes derived from BEAS-2B cell treated with cigarette smoke extract lead to RAW264.7 macrophages polarization by increasing the percentages of CD86⁺, CD80⁺, CD163⁺, and CD206⁺ cells, but also the secretion of TNF-α, IL-6, iNOS, IL-10, Arg-1, and TGF-β [56]. Exosomes derived from lung epithelium may be used to develop biomarkers for diagnosing and treating cigarette smoke-related lung diseases. Lee et al. isolated a subpopulation of miRNA-enriched EVs’ from BAL fluid using ultracentrifugation and sucrose gradient [53]. They were mainly derived from ATI cells, as indicated by caveolin-1 staining. This study provides a novel insight into underlying lung pathology mechanisms, identifying biomarkers, and developing novel therapeutic strategies. MiRNAs deregulation affects molecular pathways such as NOTCH, WNT, hypoxia-inducible factor-1A (HIF-1α), transforming growth factor, KRAS, and SMAD. They are critical for cell fate determination, inflammation, cellular responses, and survival, suggesting their involvement in COPD pathogenesis. Indeed, miRNAs and exosomes have emerged among various biomarkers as new tools for diagnosis and therapeutic applications in this disease [57].

Microvesicles (MVs) are released from many cell types, including platelets [58], endothelial cells, erythrocytes, and leukocytes. Also, they have been found in blood, urine, synovial fluid, extracellular spaces of solid organs, atherosclerotic plaques, and tumors [59]. Alveolar macrophage-derived MVs can be isolated from murine BAL fluid [60]. Also, MVs obtained from BEAS-2B cells exposed to hyperoxia were studied. These miRNA-enriched epithelial MVs triggered macrophage-mediated lung inflammatory responses [61].

MiRNAs have crucial roles in regulating lung maturation and development, including miR-17, miR-20a, miR-106b, and miR-127 [62]. Increased SP-A, SP-B, and SP-C levels in the miR-26a KO mouse model were observed. MiR-26a overexpression in rat ATII cells inhibited pulmonary surfactant synthesis by reducing SMAD1-associated BMP signaling pathways, which is critical in lung development [63]. Another study demonstrated that SP-C’s downregulation in human lung adenocarcinoma is miR-629–3p-mediated by direct binding to SP-C mRNA’ 3’UTR [64].
5. Dysregulation of miRNAs by exposure to cigarette smoke

Studies have shown the correlation between miRNAs and respiratory dysfunction. The pathogenesis of cigarette smoke-induced lung injury is poorly understood, and this exposure is a risk factor for COPD development [65]. Nouws et al. found that miR-24-3p was decreased in parenchymal lung tissue samples obtained from patients with this disease and inversely correlated with its severity (Table 1) [66]. Its inhibition increased susceptibility of ATII cells to apoptosis and emphysema development in cigarette smoke-exposed mice. Also, they detected that in primary human airway epithelial cells (HAECs) exposed to cigarette smoke extract, miR-24-3p decreased apoptosis through the BH3-only protein BIM inhibition, suppressed DNA repair protein BRCA1, and DNA damage response (DDR). Also, miR-24-3p inhibited homologous recombination (HR) but not mutagenic non-homologous end joining (NHEJ) DNA repair pathways. Degreasing cotton smoke reduced Let-7f-1-3p expression in human pulmonary alveolar epithelial cells (HPAEpiC) [67]. Let-7f-1-3p agonir attenuated smoke-induced human small airway epithelial cell (HSAEC) and HPAEpiC apoptosis by repressing the transcription factor Forkhead box O1 (FOXO1) gene expression. FOXO1 plays a pro-apoptotic role because it increases the expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), Fas ligand (Fasl), and BIM that play a fundamental role in the intrinsic and extrinsic apoptosis pathways. Paschalaki et al. found that miR-126 levels were reduced in lung tissue obtained from mice exposed to cigarette smoke for 28 days [68]. This correlated with increased ataxia-telangiectasia mutated (ATM) protein kinase expression and activation of DDR in the presence of DNA double-strand breaks. Also, decreased miR-126 expression was detected in endothelial and bronchial epithelial cells obtained from COPD patients. Moreover, its inhibition increased ATM mRNA and protein levels. These results suggest that miR-126 controls DDR by repressing ATM protein kinase activity and highlighting its importance in this disease pathogenesis. A recent study reported increased miR-155 expression in lung tissue obtained from smokers and COPD patients (Table 2) [69]. Also, its higher levels were detected in alveolar macrophages and lungs in cigarette smoke-exposed mice. Moreover, attenuation of inflammation was observed in BAL fluid and lung tissue in miR-155 deficient mice exposed to cigarette smoke for 4 weeks.

6. Role of miRNAs in emphysema patients

Numerous studies have reported aberrantly expressed miRNAs in various lung diseases [70]. However, little is known about how miRNAs contribute to emphysema development [71]. It was shown that miRNAs levels, e.g., miR-34c, miR-34b, miR-149, miR-133a, and miR-133b, were significantly down-regulated in lung tissue obtained from patients with moderate compared to mild disease [72]. The reduced miR-34c expression was also associated with increased serpin family E member 1 (SERPINE1) expression, a protease inhibitor, in BEAS-2B cells, fetal lung fibroblast HFL1 cell line in vitro, and in emphysematous lung tissue ex vivo. This indicates a potential mechanism involved in this disease progression [72]. Apoptosis of lung endothelial cells and the implication of miR-199a-5p and miR-34a have also been detected in emphysema development [73,74]. Mizuno et al. found that miR-199a-5p reduced the expression of the hypoxia-inducible factor-1α (HIF-1α) in human pulmonary microvascular endothelial cells (HPMVECs) [74].
Increased expression of miR-34a and miR-199a-5p was found in lung tissue obtained from COPD patients, which affected the HIF-1α-dependent lung structure maintenance program under the control of the p53 signaling pathway. Increased p53 expression caused by oxidative stress in HPMVECs induced miR-34a levels and reduced phosphorylation of AKT, which is known to trigger cell apoptosis. Moreover, AKT inactivation caused upregulation of miR-199a-5p, which decreased HIF-1α levels. This led to impaired VEGF expression and reduced AKT phosphorylation, contributing to HPMVECs apoptosis and emphysema development. Another study showed that increased expression of miR-638 in human lung fibroblasts correlated with this disease severity [71]. It can also regulate the pathways associated with emphysema pathophysiologies, such as oxidative stress and protein calcium regulated heat stable protein 1 (CARHSP1). Increased miR-638 levels in response to oxidative stress in lung tissue contributed to accelerated aging leading to an impaired ability to replace altered extracellular matrix (ECM) components and decreased repair in this disease [71]. Ezzie et al. showed that miR-15b is localized in the bronchial epithelium and alveolar wall at the junction of emphysematous and fibrosis areas [75]. Also, in situ hybridization indicated miR-15b localization in the bronchial epithelium and ATII cells in a smoker with COPD. A recent study on the anti-oncogenic miR-7 showed increased methylation in buccal epithelial cells in COPD. Higher miR-7 methylation was observed in emphysema which may explain the higher incidence of lung cancer in these patients [76]. Recently, Green et al. found increased miR-181b-3p, miR-23c, and miR-429 in human pulmonary endothelial cells (HPECs) in patients with COPD [77]. MiR-429 was also upregulated in lung tumors, suggesting that miRNAs alterations in COPD patients may precede the development of lung cancer.

7. Animal models of emphysema

Animal models complement studies using human samples and allow determining the role of miRNAs in emphysema development. An increased miR-22 expression was detected in lung myeloid dendritic cells (mDCs) in smokers with emphysema [78]. Its levels were high in antigen-presenting cells (APCs) in mice exposed to cigarette smoke or nanoparticulate carbon black, which promoted T_{H17} cell-dependent emphysema. Of note, a mouse model with miR-22 deficiency exhibited attenuated T_{H17} responses and failed to develop emphysema after this exposure. Moreover, it was shown that miR-22 controls APCs activation and T_{H17} responses by activating AP-1 transcription factor complexes and histone deacetylase 4 (HDAC4). The autoreactive T_{H17} cells release chemokines that recruit the elastase-secreting neutrophils and macrophages to the lung, causing elastin degradation and developing this disease [79,80]. A recent study showed miR-200b downregulation in the lung tissue in murine elastase-induced emphysema [81]. Its expression also correlated with the inflammatory response in the mouse lung epithelial MLE-12 cell line. Also, zinc finger E-box binding homeobox 2 (ZEB2), a target gene of miR-200b, plays a role in these alterations, as detected by luciferase assay. These results indicate that targeting ZEB2 by miR-200b may attenuate emphysematous changes. Recently, De Smet et al. showed attenuation of cigarette smoke-induced pulmonary inflammation in elastase-induced emphysema in mice with miR-155 deficiency [69]. This study indicates miR-155 as a potential target in COPD therapy.
In summary, downregulated miRNAs and their target signaling pathways in humans and animal models of emphysema are shown Table 1. Upregulated miRNAs are presented in Table 2.

8. Cellular senescence in emphysema

Cellular senescence is one of the major features induced by cigarette smoking and contributes to emphysema pathophysiology [82,83]. Cellular senescence is a state of growth arrest triggered by multiple mechanisms such as telomere shortening, oxidative stress, persistent DDR, or oncogene activation. COPD and IPF are among lung diseases related to aging [84]. Oxidative stress can cause premature senescence [82,85], and emphysema is associated with alveolar epithelial and endothelial cell apoptosis [37,73]. Under normal conditions, the loss of ATII cells is replaced by proliferating cells that undergo cell cycle divisions, maintaining lung homeostasis [37,39]. However, repeated cell cycles eventually cause senescence by telomere shortening leading to inhibition of proliferation and compensation of apoptotic cells [86]. Also, cigarette smoke-induced oxidative stress can cause ATII cell premature senescence without telomere shortening in this disease [86]. Studies showed that smoking increases the levels of pro-senescence markers p16, p21, and p53, and phosphorylation of the DNA damage marker γH2AX in HSAECs, fibroblasts in vitro, and murine lung [87–89]. A recent study revealed an increased p16 expression, a cell cycle inhibitor, in COPD lungs. Lungs of mice lacking p16 were structurally and functionally resistant to cigarette smoke-induced emphysema due to activation of IGF1/AKT regenerative and protective signaling and increased ATII cell proliferation. Importantly, Igf1 and Akt1 mRNAs were diminished in COPD lung [90]. Obtained results indicate that targeting senescence can promote the IGF1 proliferative pathway, facilitate re-epithelialization and lung regeneration.

The mTOR signaling activation is implicated in emphysema pathogenesis, as demonstrated using transgenic mice [91]. mTOR overactivity in lung vascular cells or alveolar epithelial cells contributed to lung senescence with rapid disease development, pulmonary hypertension, and inflammation. This suggests a novel therapeutic approach in COPD by inhibiting cellular senescence via targeting the mTOR pathway. It was also shown that the induction of AMP-activated protein kinase (AMPK) that controls energy balance and metabolism reduces inflammatory responses and expression of genes involved in cellular senescence in BEAS-2B cells, SAECs, and in a mouse model of elastase-induced emphysema [92,93]. AMPK upregulated mitochondrial proteins, antioxidant superoxide dismutase 2 (SOD2), and the histone deacetylase SIRT3 [92], which play an important role in regulating inflammation and cellular senescence [94].

Although studies identified altered signaling pathways contributing to senescence and pulmonary emphysema, miRNAs’ role in these processes is not well known. Christenson et al. showed that increased miR-638 expression, caused by emphysema-related oxidative stress in human lung fibroblasts, is implicated in activating multiple pathways such as DDR and telomere attrition [71]. This can lead to cellular senescence, the lung’s impaired ability to replace altered ECM components, and contribute to disease progression. In a recent study, Shen et al. found that miR-200b was downregulated in the murine model
of COPD, and its expression was correlated with cellular senescence and inflammatory response [81]. They showed that miR-200b acts as an anti-aging factor in the lungs. Overexpression of miR-200b in MLE-12 cells attenuated cigarette smoke extract-induced senescence-associated beta-galactosidase (SA-β-GAL) activity and deterred the increase in the TNF-α levels. MiR-200b levels were negatively correlated with ZEB2 protein and implicated in cellular senescence. ZEB2 upregulation in MLE-12 cells also induced TNF-α expression contributing to the inflammatory response. The importance of miR-200b was also highlighted in the attenuation of cellular senescence and inflammation by targeting ZEB2 in a murine model of pulmonary emphysema, which suggests a novel therapeutic target for COPD. It was reported that an increased expression of miR-34a caused by hydrogen peroxide-induced oxidative stress in BEA-S2B cells was associated with PI3Kα activation and phosphatase and tensin homolog (PTEN) reduction. A reduction of SIRT1 and SIRT6, putative anti-aging enzymes, in the BEAS-2B cell line and peripheral lung samples obtained from COPD patients was also observed. SIRT1, an NAD+-dependent protein/histone deacetylase, protected against cigarette smoke- and elastase-induced emphysema in mice through FOXO3-mediated decrease of cellular senescence. This was independent of inflammation since the NF-κB/IKK2 inhibitor did not have any beneficial effect on emphysema.

Baker et al. reported that miR-34a may serve as a potential biomarker of cellular senescence by acting as an inhibitor of SIRT1 and SIRT6 expression in COPD patients [95]. Moreover, miR-570-3p was involved in reducing SIRT1 levels and activation of cellular senescence in chronic lung diseases such as COPD and interstitial lung disease (ILD) [96]. It was activated by p38 MAP kinase and c-Jun signaling. These results suggest that miR-570-3p can serve as a therapeutic target in lung diseases, and its inhibition may restore cellular growth. Recently, Zeng et al. showed increased miR-494-3p expression in COPD lung tissue, SAECs, and BEAS-2B cells accompanied by an increase in senescence markers like p27, p21, p16, and other pro-inflammatory and profibrotic proteins associated with senescence-like IL-1β, TNF-α, MMP-2, and MMP-9 [97]. They found that miR-494-3p binds to Sirt3 and decreases its protein expression in SAECs. The SIRT3 is known to counteract oxidative stress, defend against apoptosis and protect cells from aging. Moreover, miR-494-3p expression was induced by p38 MAPK-c-myc signaling. Therefore targeting senescence through miR-494-3p may be promising approach for targeting COPD and other aging-related lung diseases.

A recent study showed the implication of miRNAs in lung aging by targeting inflammatory and apoptotic pathways [98]. They found an altered expression profile of 25 miRNAs in young and old mice lungs, 8 miRNAs were upregulated, and 17 miRNAs were downregulated. These miRNAs regulate several mRNAs associated with aging-related lung diseases, including emphysema.

### 9. MiRNAs-based therapeutic strategies

MiRNAs show great potential as treatment targets for numerous diseases [49]. Therapies that effectively slow down the accelerated decline in lung function in patients with COPD are still lacking [99]. In a recent study, Mohamed et al. demonstrated a novel potential
delivery system for miR-146a using poly (glycerol adipate-co-ω-pentadecalactone), (PGA-co-PDL), nanoparticles (NPs) as miR-146a-NP complex to treat COPD. A549 cell transfection with miR-146a-NP reduced target gene IRAK1 expression. IRAK1 regulates multiple pathways in innate and adaptive immune responses by linking several immune-receptor complexes to TNF receptor-associated factor 6 (TRAF6), leading to activation of immune signaling pathways \[100\]. MiR-146a was decreased in primary human lung fibroblasts in COPD, and its overexpression had anti-inflammatory effects by downregulating IL-8 and IRAK1 levels and the IL-1 pathway \[101\]. Further studies in COPD patient-derived lung cells are required to demonstrate miR-146a-NPs potential in clinical settings. To date, the treatment of lung diseases using miRNAs as a new class of drugs lacks details on how they can be designed for effective and specific delivery as potential therapeutics \[102\]. However, other approaches targeting dysregulated miRNAs can be used in emphysema. For example, miRNAs antagonists, such as anti-miRNAs, can lock nucleic acids and antagomiRs \[103\]. Indeed, it has been shown that inhibiting miR-638 in human lung fibroblasts led to the modulation of emphysema-related pathways \[71\]. Also, miR-200b, which is downregulated in mice with elastase-induced emphysema, may serve as a potential novel therapy targeting ZEB2 \[81\]. Others described treatments in BEAS-2B cells and human primary bronchial epithelial cells obtained from COPD patients using antagomiRs against miR-15b and miR-34a, which are upregulated in lung tissue in individuals with this disease \[75,95\]. The loss of SIRT1 and SIRT6 expression by miR-34a increased cellular senescence markers in airway epithelial cells obtained from individuals with COPD. They are implicated in several biological processes, including inflammation, cellular senescence, DDR, genomic stability, and autophagy; via the deacetylation of upstream regulatory proteins. AntagomiRs against miR-34a restored SIRT1 and SIRT6 levels. Also, targeting miR-570–3p by antagomiRs in SAECs obtained from COPD patients reversed aging by restoring SIRT1 expression and suppressing p16, p21, and p27 levels. This suggests that restoring cell cycle progression and preventing senescence can lead to cellular growth and attenuating the accelerated aging phenotype in COPD \[96\]. There are recent advances on inhaled RNA-based therapeutics using a dry powder form as a novel approach for COPD \[104\]. However, transcending the biological barrier of lungs and successfully reaching deep lung regions is still challenging. Further studies are needed to find appropriate, effective, and safe systems for miRNA-based treatments in COPD.

10. Conclusion

This review described the current knowledge of miRNAs dysregulation in pulmonary emphysema (Fig. 1). We highlighted their contribution to disease severity. Moreover, we focused on pathways implicated in pro-inflammatory responses, DNA damage, cell senescence, and apoptosis. Also, the potential use of miRNAs as biomarkers is the primary approach of research. Furthermore, treating lung diseases using miRNAs as a new class of drugs is limited due to complex challenges. Further studies on miRNAs are urgently needed, which can lead to the development of novel therapeutic approaches.
Acknowledgments

This work was supported by R21 ES030808 (KB), the Catalyst Award from American Lung Association (KB), and R01 ES032081 and R01 HL150587 (BK).

References

[1]. Warburton DSM, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV, The molecular basis of lung morphogenesis, Mech. Dev 92 (1) (2000) 55–81. [PubMed: 10704888]

[2]. Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, Randell SH, Noble PW, Hogan BL, Type 2 alveolar cells are stem cells in adult lung, J. Clin. Investig 123 (7) (2013) 3025–3036. [PubMed: 23921127]

[3]. Kosmider B, Lin CR, Karim L, Tomar D, Vlasenko L, Marchetti N, Bolla S, Madesh M, Criner GJ, Bahmed K, Mitochondrial dysfunction in human primary alveolar type II cells in emphysema, EBioMedicine 46 (2019) 305–316. [PubMed: 31383554]

[4]. Tsuji TAK, Nagai A, Cigarette smoke induces senescence in alveolar epithelial cells, Am. J. Respir. Cell Mol. Biol 31 (6) (2004) 643–649. [PubMed: 15333326]

[5]. An JBS, Epidemiological overview of chronic obstructive pulmonary disease: what can real-life data tell us about disease management? COPD 14 (sup1) (2017) S3–S7. [PubMed: 28306356]

[6]. Dass CGA, Daf K, Kumaran M, Steiner R, Criner GJ, Role of imaging in bronchoscopic lung volume reduction using endobronchial valve: state of the art review. J Thorac Imaging, 2020.

[7]. Barnes PJAG, Fagerlås M, Belvisi MG, Chronic lung diseases: prospects for regeneration and repair, Eur. Respir. Rev 30 (159) (2021), 200213. [PubMed: 33408088]

[8]. Hisata S, Racanelli AC, Kermani P, Schreiner R, Houghton S, Palikuqi B, Kumar B, Zhou A, McColl K, Capili A, Redmond D, Nolan DJ, Ginsberg M, Ding BS, Martinez FJ, Scandura JM, Crooan SM, Rafii S, Choi A, Reversal of emphysema by restoration of pulmonary endothelial cells, J. Exp. Med 218 (8) (2021), e20200938. [PubMed: 34287647]

[9]. Valinezhad Orang ASR, Kazemzadeh-Bavili M, Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation, Int. J. Genom 2014 (2014), 970607.

[10]. Szymczak IWJ, Pawliczak R, Molecular background of miRNA role in asthma and COPD: an updated insight, Biomed. Res. Int 2016 (2016), 7802521. [PubMed: 27376086]

[11]. Stone KCMR, Gehr P, Stockstill B, Crapo JD, Allometric relationships of cell numbers and size in the mammalian lung, Am. J. Respir. Cell Mol. Biol 6 (2) (1992) 235–243. [PubMed: 1540387]

[12]. LG D, Isolation and culture of alveolar type II cells, Am. J. Physiol 258 (4 Pt 1) (1990) L134–L147. [PubMed: 2185652]

[13]. Lee DFSF, Grainger D, Francis RJ, MacLellan-Gibson K, Chambers MA, Isolation and characterisation of alveolar type II pneumocytes from adult bovine lung, Sci. Rep (2018) 11927. [PubMed: 30093682]

[14]. Andreeva AV, Kutuzov MA, Voyno-Yasnetskaya TA, Regulation of surfactant secretion in alveolar type II cells, Am. J. Physiol. Lung Cell Mol. Physiol 293 (2) (2007) L259–L271. [PubMed: 17496061]

[15]. Wert SE, Yoshida M, Levine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA, Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice, Proc. Natl. Acad. Sci. USA 97 (11) (2000) 5972–5977. [PubMed: 10801980]

[16]. Dobbs LGJM, Alveolar epithelial transport in the adult lung, Respir. Physiol. Neurobiol 159 (3) (2008) 283–300. [PubMed: 17689299]

[17]. Johnson MDWJ, Allen L, Barby P, Dobbs LG, Alveolar epithelial type I cells contain transport proteins and transport sodium, supporting an active role for type I cells in regulation of lung liquid homeostasis, Proc. Natl. Acad. Sci. USA 99 (4) (2002) 1966–1971. [PubMed: 11842214]

[18]. Ridge KM, Olivera WG, Saldias F, Azzam Z, Horowitz S, Rutschman DH, Dumasius V, Factor P, Szajider J, Alveolar type 1 cells express the alpha2 Na, K-ATPase, which contributes to lung liquid clearance, Circ. Res 92 (4) (2003) 453–460. [PubMed: 12600893]
[19]. Kosmider BLJ, Murphy RC, Mason RJ, Apoptosis induced by ozone and oxysterols in human alveolar epithelial cells, Free Radic. Biol. Med 48 (11) (2010) 1513–1524. [PubMed: 20219673]

[20]. Kosmider B, Messier EM, Janssen WJ, Nahreini P, Wang J, Hartshorn KL, Mason RJ, Nrf2 protects human alveolar epithelial cells against injury induced by influenza A virus, Respir. Res 13 (1) (2012) 43. [PubMed: 22672594]

[21]. Wu ASH, Regulation of alveolar type 2 stem/progenitor cells in lung injury and regeneration, Acta Biochim. Biophys. Sin 52 (7) (2020) 716–722. [PubMed: 32445469]

[22]. Mercer BALV, Powell CA, D’Armiento J, The epithelial cell in lung health and emphysema pathogenesis, Curr. Respir. Med. Rev 2 (2) (2006) 101–142. [PubMed: 19662102]

[23]. Aspal MZR, Mechanisms of ATII-to-ATI cell differentiation during lung regeneration, Int. J. Mol. Sci 21 (9) (2020) 3188.

[24]. Mathers CDLD, Projections of global mortality and burden of disease from 2002 to 2030, PLoS Med 3 (11) (2006) 442.

[25]. Quaderi SAHJ, The unmet global burden of COPD, Glob. Health Epidemiol. Genom 3 (2018) 4.

[26]. Bhatt SP, Washko GR, Hoffman EA Jr., Newell JD Jr, Bodduluri S, Diaz AA, Galban CJ, Silverman EK, San José Estépar R, Lynch DA, Imaging advances in chronic obstructive pulmonary disease. Insights from the genetic epidemiology of chronic obstructive pulmonary disease (COPDGene) study, Am. J. Respir. Crit. Care Med 199 (3) (2019) 286–301. [PubMed: 30304637]

[27]. Brandsma C.A.Vd.B.M., Hackett TL, Brusselle G, Timens W, Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine, J. Pathol 250 (5) (2020) 624–635. [PubMed: 31691283]

[28]. Morissette MCPJ, Milot J, Alveolar epithelial and endothelial cell apoptosis in emphysema: what we know and what we need to know, Int. J. Chron. Obstruct. Pulmon. Dis 4 (2009) 19–31. [PubMed: 19436685]

[29]. Tuder RMYT, Arap W, Pasqualini R, Petrache I, State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective, Proc. Am. Thorac. Soc 3 (2006) 503–510. [PubMed: 16921129]

[30]. Boukhenouna SWM, Bahmed K, Kosmider B, Reactive oxygen species in chronic obstructive pulmonary disease, Oxid. Med. Cell Longev 2018 (2018), 5730395. [PubMed: 29599897]

[31]. Kosmider BME, Chu HW, Mason RJ, Human alveolar epithelial cell injury induced by cigarette smoke, PLoS One 6 (12) (2011) 26059.

[32]. Kim C, Lee JM, Park SW, Kim KS, Lee MW, Paik S, Jang AS, Kim DJ, Uh S, Kim Y, Park CS, Attenuation of cigarette smoke-induced emphysema in mice by apolipoprotein A-1 overexpression, Am. J. Respir. Cell Mol. Biol 54 (1) (2016) 91–102. [PubMed: 26086425]

[33]. Cazzola MSD, Rogliani P, Matera MG, α1-Antitrypsin deficiency and chronic respiratory disorders, Eur. Respir. Rev 29 (155) (2020), 190073. [PubMed: 32051168]

[34]. Janosz E, Hetzel M, Spielmann H, Tumpara S, Rossdamm C, Schwabbaumer M, Kloos D, von Kaisenberg C, Schambach A, Buettner F, Janciauskienė S, Lachmann N, Moritz T, Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo, Gene Ther (2021).

[35]. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, MacNee W, De Boer WI, 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med 166 (4) (2002) 490–495. [PubMed: 12186826]

[36]. Brusselle G Gig, Bracke KR, New insights into the immunology of chronic obstructive pulmonary disease, Lancet 378 (9795) (2011) 1015–1026. [PubMed: 21907865]

[37]. Yokohori NAK, Nagai A, Respiratory Failure Research Group in Japan, Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema, Chest 125 (2) (2004) 626–632. [PubMed: 14769747]

[38]. Bahmed K, Messier EM, Zhou W, Tuder RM, Freed CR, Chu HW, Kelsen SG, Bowler RP, Mason RJ, Kosmider B, DJ-1 modulates nuclear erythroid 2-related factor-2-mediated protection in human primary alveolar type II cells in smokers, Am. J. Respir. Cell Mol. Biol 55 (3) (2016) 439–449. [PubMed: 27093578]
[39]. Imai KMB, Schulman LL, Sonett JR, D’Armiento JM, Correlation of lung surface area to apoptosis and proliferation in human emphysema, Eur. Respir. J 25 (2) (2005) 250–258. [PubMed: 15684288]

[40]. Bartel DP, MicroRNAs: target recognition and regulatory functions, Cell 136 (2) (2009) 215–233. [PubMed: 19167326]

[41]. Esteller M, Non-coding RNAs in human disease, Nat. Rev. Genet 12 (12) (2011) 861–874. [PubMed: 22094949]

[42]. O’Brien JHH, Zayed Y, Peng C, Overview of microRNA biogenesis, mechanisms of actions, and circulation, Front. Endocrinol 9 (2018) 402.

[43]. Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi S, Exosome and exosomal microRNA: trafficking, sorting, and function, Genom. Proteom. Bioinforma 13 (1) (2015) 17–24.

[44]. Borralho PMRC, Steer CJ, microRNAs in mitochondria: an unexplored niche, Adv. Exp. Med. Biol 887 (2015) 31–51. [PubMed: 26662985]

[45]. Li ZF, Liang YM, Lau PN, Shen W, Wang DK, Cheung WT, Xue CJ, Poon LM, Lam YW, Dynamic localisation of mature microRNAs in Human nucleoli is influenced by exogenous genetic materials, PLoS One 8 (8) (2013) 70869.

[46]. Guiot JSI, Louis E, Louis R, Malaise M, Njock MS, Exosomal miRNAs in lung diseases: from biologic function to therapeutic targets, J. Clin. Med 8 (9) (2019) 1345.

[47]. Zhu HFG, Extracellular/circulating microRNAs and their potential role in cardiovascular disease, Am. J. Cardiovase. Dis 1 (2) (2011) 138–149. [PubMed: 22059153]

[48]. Vickers KCPB, Shoucri BM, Shamburek RD, Remaley AT, MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins, Nat. Cell Biol 13 (4) (2011) 423–433. [PubMed: 21423178]

[49]. Sato TBH, Rennard SI, Seyama K, Takahashi K, MicroRNAs as therapeutic targets in lung disease: prospects and challenges, Chronic Obstr. Pulm. Dis 3 (1) (2015) 382–388. [PubMed: 28848860]

[50]. Brown DRM, Nana-Sinkam SP, MicroRNAs in respiratory disease. A clinician’s overview, Ann. Am. Thorac. Soc 11 (8) (2014) 1277–1285. [PubMed: 25172373]

[51]. Gon YST, Mizumura K, Maruoka S, Hikichi M, Molecular techniques for respiratory diseases: MicroRNA and extracellular vesicles, Respirology 25 (2) (2020) 149–160. [PubMed: 31872560]

[52]. éliot ALY, Roy Saint-Georges F, Gossel P, Fatteyn RO, Courcet D, Martin PJ, Smoker extracellular vesicles influence status of human bronchial epithelial cells, Int. J. Hyg. Environ. Health 220 (2 Pt B) (2017) 445–454. [PubMed: 28063900]

[53]. Lee HGM, Pinilla-Vera M, Fredenburgh LE, Jin Y, Identification of miRNA-rich vesicles in bronchoalveolar lavage fluid: Insights into the function and heterogeneity of extracellular vesicles, J. Control Release 294 (2019) 43–52. [PubMed: 30529727]

[54]. Li YYZ, Fan J, Zhang S, Yang W, The roles of exosomal miRNAs and IncRNAs in lung diseases, Signal Transduct. Target Ther 4 (2019) 47. [PubMed: 31728212]

[55]. Benedikter BJ, Volgers C, van Eijck PH, Wouters E, Savelkoul P, Reynaert NL, Hoen G, Rohde G, Weseler AR, Rassam F, Cigarette smoke extract induced exosome release is mediated by depletion of exofacial thiols and can be inhibited by thiol-antioxidants, Free Radic. Biol. Med 108 (2017) 334–344. [PubMed: 28359953]

[56]. Chen Z, Wu H, Shi R, Fan W, Zhang J, Su W, Wang Y, Li P, miRNAomics analysis reveals the promoting effects of cigarette smoke extract-treated Beas-2Bderived exosomes on macrophage polarization, Biochem. Biophys. Res. Commun 572 (2021) 157–163. [PubMed: 34365140]

[57]. Salimian JMH, Moridikia A, Harchegani AB, Salehka A, Salehi H, Chronic obstructive pulmonary disease: microRNAs and exosomes as new diagnostic and therapeutic biomarkers, J. Res. Med. Sci 23 (23) (2018) 27. [PubMed: 29692824]

[58]. Melki ITN, Zufferey A, Boilard E, Platelet microvesicles in health and disease, Platelets 28 (3) (2017) 214–221. [PubMed: 28102737]

[59]. György B, Módos K, Pállinger E, álóczyi K, Pásztói M, Misják P, Deli MA, Cipos A, Szalai A, Voszka I, Polgár A, Tóth K, Csete M, Nagy G, Gay S, Falus A, Kíttel A, Buzás EI, Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters, Blood 117 (4) (2011) e39–e48. [PubMed: 21041717]
[60]. Soni S, Wilson MR, O’dea KP, Yoshida M, Katbeh U, Woods SJ, Takata M, Alveolar macrophage-derived microvesicles mediate acute lung injury, Thorax 71 (11) (2016) 1020–1029. [PubMed: 27287089]

[61]. Lee HZD, Zhu Z, Dela Cruz CS, Jin Y, Epithelial cell-derived microvesicles activate macrophages and promote inflammation via microvesicle-containing microRNAs, Sci. Rep 6 (6) (2016) 35250. [PubMed: 27731391]

[62]. Sun YF, Kan Q, Yang Y, Zhang YH, Shen JX, Zhang C, Zhou XY, Knockout of microRNA-26a promotes lung development and pulmonary surfactant synthesis, Mol. Med. Rep 17 (4) (2018) 5988–5995. [PubMed: 29436664]

[63]. Zhang XQ, Zhang P, Yang Y, Qiu J, Kan Q, Liang HL, Zhou XY, Zhou XG, Regulation of pulmonary surfactant synthesis in fetal rat type II alveolar epithelial cells by microRNA-26a, Pedia Pulmonol. 49 (9) (2014) 863–872.

[64]. Li B, Meng YQ, Li Z, Yin C, Lin JP, Zhu DJ, Zhang SB, MiR-629–3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma, Artif. Cells Nanomed. Biotechnol 47 (2019) 3286–3296. [PubMed: 31379200]

[65]. Salvi S, Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease, Clin. Chest Med 35 (1) (2014) 17–27. [PubMed: 24507834]

[66]. Nouws JWF, Finnemore E, Roque W, Kim SJ, Bazan IS, et al., MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease, JCI Insight 8 (2020), 134218.

[67]. Han ZZY, Cui Z, Guo P, Wei A, Meng Q, MicroRNA Let-7f-1-3p attenuates smoke-induced apoptosis in bronchial and alveolar epithelial cells in vitro by targeting FOXO1, Eur. J. Pharmacol 862 (2019), 172531. [PubMed: 31301310]

[68]. Paschalaki KE, Zampetaki A, Baker JR, Birrell MA, Starke RD, Belvisi MG, Donnelly LE, Mayr M, Randi AM, Barnes PJ, Downregulation of MicroRNA-126 augments DNA damage response in cigarette smokers and patients with chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med 197 (5) (2018) 665–668. [PubMed: 28753388]

[69]. De Smet EG, Van Eeckhoutte HP, Avila Cobos F, Blomme E, Verhamme FM, Provoost S, Verleden SE, Venken K, Maes T, Joos GF, Mestdagh P, Bracke KR, The role of miR-155 in cigarette smoke-induced pulmonary inflammation and COPD, Mucosal Immunol 13 (3) (2020) 423–436. [PubMed: 31819170]

[70]. Oglesby IK, MicroRNAs in inflammatory lung disease–master regulators or target practice? Respir. Res 11 (1) (2010) 148. [PubMed: 21029443]

[71]. Christenson SA, miR-638 regulates gene expression networks associated with emphysematous lung destruction, Genome Med 5 (12) (2013) 114. [PubMed: 24380442]

[72]. Savarimuthu Francis SM, Davidson MR, Tan ME, Wright CM, Clarke BE, Duhi CG, Bowman RV, Hayward NK, Fong KM, Yang IA, MicroRNA-34c is associated with emphysema severity and modulates SERPINE1 expression, BMC Genom. 15 (2014) 88.

[73]. Kasahara YTR, Cool CD, Lynch DA, Flores SC, Voelkel NF, Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema, Am. J. Respir. Crit. Care Med 163 (3 Pt 1) (2001) 737–744. [PubMed: 11255433]

[74]. Mizuno SBH, Gomez-Arroyo J, Alhusaini A, Kraskauskas D, Cool CD, Voelkel NF, MicroRNA-199a-5p is associated with hypoxia-inducible factor-1α expression in lungs from patients with COPD, Chest 142 (3) (2012) 663–672. [PubMed: 22383663]

[75]. Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R, Batte K, Yu L, Nuovo G, Galas D, Diaz P, Wang K, Nana-Sinkam SP, Gene expression networks in COPD: microRNA and mRNA regulation, Thorax 67 (2) (2012) 122–131. [PubMed: 21940491]

[76]. Rosas-Alonso R, Galera R, Sánchez-Pascual JJ, Casitas R, Burdiel M, Martínez-Cerón E, Vera O, Rodríguez-Antolín C, Pernía O, De Castro J, García-Rio F, Ibanez-de-Cáceres I, Hypermethylation of anti-oncogenic microRNA 7 is increased in emphysema patients, Arch. Bronconeumol 56 (8) (2020) 506–513. [PubMed: 31780284]
[77]. Green CECJ, Bicknell R, Turner AM, Pulmonary microRNA changes alter angiogenesis in chronic obstructive pulmonary disease and lung cancer, Biomedicines 9 (7) (2021) 830. [PubMed: 34356894]

[78]. Lu W, You R, Yuan X, Yang T, Samuel EL, Marcano DC, Sikkema WK, Tour JM, Rodriguez A, Kheradmand F, Corry DB. The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote T(H)17 cell-dependent emphysema, Nat. Immunol 16 (11) (2015) 1185–1194. [PubMed: 26437241]

[79]. Shan M, Cheng HF, Song LZ, Roberts L, Green L, Hacken-Bitar J, Huh J, Bakaean F, Coxson HO, Storness-Bliss C, Ramechandani M, Lee SH, Corry DB, Kheradmand F, Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema, Sci. Transl. Med 1 (4) (2009) 4.

[80]. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, Kheradmand F, An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema, PLoS Med. 1 (1) (2004) 8.

[81]. Shen ZXW, Wang H, Sun F, Zhang C, Gong Q, Ge S, miR-200b regulates cellular senescence and inflammatory responses by targeting ZEB2 in pulmonary emphysema, Artif. Cells Nanomed. Biotechnol 48 (1) (2020) 656–663. [PubMed: 32070140]

[82]. Nyunoya T, Monick MM, Klingelhutz AL, Glaser H, Cagley JR, Brown CO, Matsumoto E, Aykin-Burns N, Spitz DR, Oshima J, Hunninghake GW, Cigarette smoke induces cellular senescence via Werner’s syndrome protein down-regulation, Am. J. Respir. Crit. Care Med 179 (4) (2009) 279–287. [PubMed: 19011155]

[83]. Nyunoya TMM, Klingelhutz A, Yarovinsky TO, Cagley JR, Hunninghake GW, Cigarette smoke induces cellular senescence, Am. J. Respir. Cell Mol. Biol 35 (6) (2006) 681–688. [PubMed: 16840774]

[84]. Chilosi MCA, Rossi A, Poletti V, Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema, Transl. Res 162 (3) (2013) 156–173. [PubMed: 23831269]

[85]. Liu A, Wu J, Li A, Bi W, Liu T, Cao L, Liu Y, Dong L, The inhibitory mechanism of Cordyceps sinensis on cigarette smoke extract-induced senescence in human bronchial epithelial cells, Int. J. Chron. Obstruct Pulmon Dis 11 (2016) 1721–1731. [PubMed: 27555762]

[86]. Tsuji TAK, Nagai A, Alveolar cell senescence in patients with pulmonary emphysema, Am. J. Respir. Crit. Care Med 174 (8) (2006) 886–893. [PubMed: 16888288]

[87]. Sundar IKRK, Sellix MT, Rahman I, The nuclear receptor and clock gene REVERBα regulates cigarette smoke-induced lung inflammation, Biochem. Biophys. Res. Commun 493 (4) (2017) 1390–1395. [PubMed: 28974420]

[88]. Ahmad TSI, Tormos AM, Lerner CA, Gerloff J, Yao H, Rahman I, Shelterin telomere protection protein 1 reduction causes telomere attrition and cellular senescence via sirtuin 1 deacetylase in chronic obstructive pulmonary disease, Am. J. Respir. Cell Mol. Biol 56 (1) (2017) 38–49. [PubMed: 27559927]

[89]. Yao HSI, Gorbunova V, Rahman I, P21-PARP-1 pathway is involved in cigarette smoke-induced lung DNA damage and cellular senescence, PLoS One 8 (11) (2013) 80007.

[90]. Cottage CT, Peterson N, Kearley J, Berlin A, Xiong X, Huntley A, Zhao W, Brown C, Migneault A, Zerrouki K, Criner G, Kolbeck R, Connor J, Lemaire R, Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice, Commun. Biol 2 (2019) 307. [PubMed: 31428695]

[91]. Houssaini A, Breau M, Kebe K, Abid S, Marcos E, Lipskaia L, Rideau D, Parpaleix A, Huang J, Anslemel V, Vienney N, Validere P, Maître B, Attwe A, Lukas C, Vindrieux D, Boczkowski J, Derumeaux G, Pare M, Bernard D, Meiners S, Adnot S, miTOR pathway activation drives lung cell senescence and emphysema, JCI Insight 3 (3) (2018), e93203.

[92]. Cheng XYLY, Huang C, Li J, Yao HW, AMP-activated protein kinase reduces inflammatory responses and cellular senescence in pulmonary emphysema, Oncotarget 8 (14) (2017) 22513–22523. [PubMed: 28186975]

[93]. Mihaylova MMSR, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism, Nat. Cell Biol 13 (9) (2011) 1016–1023. [PubMed: 21892142]
[94]. Yue LYH, Mitochondrial dysfunction in inflammatory responses and cellular senescence: pathogenesis and pharmacological targets for chronic lung diseases, Br. J. Pharmacol 173 (15) (2016) 2305–2318. [PubMed: 27189175]

[95]. Baker JR, Vuppusetty C, Colley T, Papaioannou AI, Fenwick P, Donnelly L, Ito K, Barnes PJ, Oxidative stress dependent microRNA-34a activation via PI3Ka reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells, Sci. Rep 6 (2016) 35871. [PubMed: 27767101]

[96]. Baker JR, Vuppusetty C, Colley T, Hassibi S, Fenwick PS, Donnelly LE, Ito K, Barnes PJ, MicroRNA-570 is a novel regulator of cellular senescence and inflammaging, FASEB J. 33 (2) (2018) 1605–1616. [PubMed: 30156909]

[97]. Zeng QZJ, Inhibition of miR-494-3p alleviates oxidative stress-induced cell senescence and inflammation in the primary epithelial cells of COPD patients, Int. Immunopharmacol 92 (2021), 107044. [PubMed: 33461161]

[98]. Calyeca JB-MY, Selman M, Pardo A, Transcriptomic profile of the mice aging lung is associated with inflammation and apoptosis as important pathways, Aging 13 (9) (2021) 12378–12394. [PubMed: 33982668]

[99]. Bracke KRMP, MicroRNAs as future therapeutic targets in COPD? Eur. Respir. J 49 (5) (2017), 1700431. [PubMed: 28546263]

[100]. Mohamed AKN, Ross K, Hutcheon GA, Saleem IY, Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD), Eur. J. Pharm. Biopharm 136 (2019) 1–8. [PubMed: 30615927]

[101]. Osei ET, Florez-Sampedro L, Tasena H, Faiz A, Noordhoek JA, Timens W, Postma DS, Hackett TL, Heijink IH, Brandsma CA, miR-146a-5p plays an essential role in the aberrant epithelial-fibroblast cross-talk in COPD, Eur. Respir. J 49 (5) (2017), 1602538. [PubMed: 28546273]

[102]. Dua KHN, Foster PS, Hansbro PM, MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases, Drug Deliv. Transl. Res 7 (1) (2017) 168–178. [PubMed: 27848224]

[103]. Osei ETF-SL, Timens W, Postma DS, Heijink IH, Brandsma CA, Unravelling the complexity of COPD by microRNAs: it’s a small world after all, Eur. Respir. J 46 (3) (2015) 807–818. [PubMed: 26250493]

[104]. Xu YTA, Zhang Y, Foged C, Inhaled RNA therapeutics for obstructive airway diseases: recent advances and future prospects, Pharmaceutics 13 (2) (2021) 177. [PubMed: 33525500]
Fig. 1.
A conceptual model of miRNAs dysregulation in alveolar epithelial cells in emphysema. Exposure to cigarette smoke causes alveolar epithelial cell dysfunction and miRNAs dysregulation causing mRNAs expression alteration. ROS contributes to alveolar epithelial cell senescence and apoptosis leading to emphysema development.
### Table 1
Downregulated miRNA in pulmonary emphysema in human samples and animals.

| Downregulated miRNA in emphysema | Upregulated pathways                      | Human samples and mice models                                      | References |
|----------------------------------|------------------------------------------|-------------------------------------------------------------------|------------|
| miR-24-3p                        | BIM and BRCA1, HR, apoptosis             | HAECs                                                             | [66]       |
| miR-34c                          | SERPINE1, MAP4K4, ZNF3, ALDOA and HNF4A  | BEAS-2B cells                                                     | [72]       |
| miR-126                          | ATM                                      | Murine lung tissue Human endothelial and bronchial epithelial cells | [68]       |
| miR-200b                         | ZEB2                                     | Murine elastase-induced emphysema MLE-12 cell line                | [81]       |
| miR-34b, miR-149, miR-133a and miR-133b | NA                                      | Human lungs tissue                                                | [72]       |

Abbreviations: HAECs - Human Airway Epithelial Cells, NA - not available
| Upregulated miRNA in emphysema | Affected pathways | Human samples and mice models | References |
|--------------------------------|------------------|-------------------------------|------------|
| miR-15b                        | Decreased SMAD7   | Human bronchial epithelium and ATII cells | [75]       |
| miR-22                         | Decreased HDAC4 expression Increased T helper 17 response | Murine model with miR-22 deficiency | [78]       |
| miR-34a and miR-199a-5p        | Decreased AKT phosphorylation HIF-1α and VEGF expression through p53 signaling | HPMVECs and BEAS-2B cells | [74]       |
| miR-638                        | Increased DNA damage Decreased DNA repair | Human lung fibroblasts | [71]       |
| miR-520e, miR-302d, miR-92a, miR-211 and miR-150 | NA                | Human lungs tissue | [71]       |
| let-7c, let-7d, let-7e, let-7f, miR-181c, miR-181d, miR-30a-3p | NA                | Human lungs tissue | [71]       |
| miR-7 methylation              | NA                | Human buccal epithelial samples | [76]       |
| miR-155                        | NA                | Human and murine lung tissue Murine alveolar macrophages | [69]       |
| miR-181b-3p, miR-23c and miR-429 | NA                | Human pulmonary endothelial cells | [77]       |
| miR-494-3p                     | Decreased SIRT3 Increased p27, p21, and p16 | Human lung tissue, SAECs, and BEAS-2B cells | [97]       |

Abbreviations: HPMVECs - Human Pulmonary Microvascular Endothelial Cells, SAECs – Small Airway Epithelial Cells, NA – not available